Nicorette

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Retrieved on: 
Tuesday, September 19, 2023
Surgery, Health, Medical Devices, Ankle, Nicorette, OTS, Surgeon, University, Lapidus, American Orthopaedic Foot and Ankle Society, SYK, Convention, Foot, Expert, Utility, Multimedia, Stryker Corporation, National Primate Research Exhibition Hall, Patient, MIS, NYSE, Dentistry, Cotton

The system will debut at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Louisville, Ky., Sept. 20-23 (booth no.

Key Points: 
  • The system will debut at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Louisville, Ky., Sept. 20-23 (booth no.
  • View the full release here: https://www.businesswire.com/news/home/20230919818115/en/
    Stryker's PROstep® MIS Lapidus is a new internal fixation system intended for treating bunions using a minimally invasive surgical reduction of hallux valgus deformity and subsequent fusion of the first metatarsal cuneiform joint.
  • The new technology features MIS joint preparation, triplanar reduction, and a three-screw construct designed to create a tension band for biomechanical stability.
  • Stryker is now the exclusive distributor of the OTS that contains the wedge implants for osteotomies of the foot.

Haleon and Microsoft use AI to enhance health product accessibility for people who are blind or partially sighted

Retrieved on: 
Thursday, October 13, 2022
Nexium, App Store (iOS/iPadOS), CDC, List of toothpaste brands, Ibuprofen, Policy, Android, Diclofenac, NYSE, Multimedia, Severe cognitive impairment, Microsoft, Nasdaq, Artificial intelligence, Technology, Mental health, Partnership, HLN, Health, Fibre supplements, AI, Seeing AI, Dentistry, MSFT, ChapStick, Nicorette, Centrum, 1-Docosanol, Aspirin/paracetamol/caffeine, TUMS, Wellness, Engineering, Medical device, Pharmaceutical industry, Video game console, Esomeprazole, Parodontax, Cold medicine, Fluticasone propionate, Sensodyne

REDMOND, Wash., Oct. 12, 2022 /PRNewswire/ -- On Wednesday, Haleon, a global leader in consumer health, and Microsoft Corp. announced a new collaboration to make everyday health more accessible for people who are blind, have low vision or have difficulty reading product labels due to low literacy. Together, the companies are expanding functionality in the Microsoft Seeing AI app to provide consumers with more detailed labelling information for over 1,500 Haleon products across the U.S. and U.K. Seeing AI is a free mobile app designed to help people who have trouble seeing by narrating the world around them.              

Key Points: 
  • - New enhancements in the free Microsoft Seeing AI app will help advance inclusivity and improve accessibility.
  • Seeing AI is a free mobile app designed to help people who have trouble seeing by narrating the world around them.
  • With today's launch on World Sight Day, people will hear packaging information through Seeing AI by scanning the barcode of Haleon products.
  • Haleon initiated this collaboration with Microsoft via its Seeing AI app to make consumer health more accessible, achievable and inclusive.

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 21, 2022
Alivecor, Health care, Central nervous system, Central Waqf Council, Face, GSK, Industry, Patient, Physician, Technology, NIHR, Drug development, Dementia, Sleep, Reckitt, Disease, Time, Company, DDF, Neurological disorder, Doctor of Philosophy, Science, LifeArc, Nicorette, MD, J&J, Health, Language, Thought, CEO, Biopharma LLC, Novartis, HIV disease progression rates, ML, Neurodegeneration, Machine learning, Brain, Psychiatry, Biomarker, Cros, Solution, Diagnosis, Caregiver, CNS, EEG, Pfizer, Pharmaceutical industry, Medical imaging, Takeda, Neurology, Cumulus cloud, Sanofi, Neuropsychiatry, Alzheimer's disease

BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO). Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase. Dr. Bhatti's appointment follows the recent award of a £1.5M UK National Institute for Health and Care Research (NIHR) grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis. 

Key Points: 
  • Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital Biomarker Platform To Accelerate Patient Care and Drug Development in Neurology and Neuropsychiatry
    BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).
  • Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase.
  • "Neurological disorders are a global health issue, and digital biomarkers which require integrated, multi-domain assessment technologies are key to supporting faster drug development, disease diagnosis, and therapeutic solutions," said Ruth McKernan, PhD, co-founder & executive chair, Cumulus.
  • The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 21, 2022
Alivecor, Health care, Central nervous system, Central Waqf Council, Face, GSK, Industry, Patient, Physician, Technology, NIHR, Drug development, Dementia, Sleep, Reckitt, Disease, Time, Company, DDF, Neurological disorder, Doctor of Philosophy, Science, LifeArc, Nicorette, MD, J&J, Health, Language, Thought, CEO, Biopharma LLC, Novartis, HIV disease progression rates, ML, Neurodegeneration, Machine learning, Brain, Psychiatry, Biomarker, Cros, Solution, Diagnosis, Caregiver, CNS, EEG, Pfizer, Pharmaceutical industry, Medical imaging, Takeda, Neurology, Cumulus cloud, Sanofi, Neuropsychiatry, Alzheimer's disease

BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO). Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase. Dr. Bhatti's appointment follows the recent award of a £1.5M UK National Institute for Health and Care Research (NIHR) grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis.   

Key Points: 
  • Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital Biomarker Platform To Accelerate Patient Care and Drug Development in Neurology and Neuropsychiatry
    BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).
  • Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase.
  • "Neurological disorders are a global health issue, and digital biomarkers which require integrated, multi-domain assessment technologies are key to supporting faster drug development, disease diagnosis, and therapeutic solutions," said Ruth McKernan, PhD, co-founder & executive chair, Cumulus.
  • The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

Nicorette is Motivating Smokers to Take Healthier Breaks with a Customized Music Listening Experience, SmokeLess Break Beats

Retrieved on: 
Wednesday, July 27, 2022
Smoke, Nexium, Brain, Smoker, Occupational burnout, Nicotine, Wellness, Heart rate, Nicotine replacement therapy, Diclofenac, Student, Music therapy, Ideation, Tobacco, NYSE, Smoking, Berklee College of Music, Solution, Fatigue, Aspirin/paracetamol/caffeine, Health, Dentistry, NRT, Marketing, Relaxation, ChapStick, Centrum, TUMS, Science, Ibuprofen, Fibre supplements, Mindfulness, Program, 1-Docosanol, Nicorette, HLN, Music, Spotify, Esomeprazole, Cold medicine, Parodontax, Fluticasone propionate, Music, Sensodyne

WARREN, N.J., July 27, 2022 /PRNewswire/ -- Today, Nicorette unveils SmokeLess Break Beats – a first-of-its kind, customized music listening experience that uses the science of music therapy to address smokers' needs and motivate them towards healthier breaks. Nicorette has partnered with Berklee Music and Health Institute to enlist 30+ students and faculty to design eight original tracks, referencing scientific research about overcoming smoking addiction. These original compositions are featured in four playlists that promote relaxation, focus, confidence, and physical release, which are key benefits smokers seek in smoke breaks. Available for free on Spotify, each playlist contains the original tracks and is personalized using the listener's music history, functioning as a break-time emotional and behavioral tool to aid in smoking cessation.

Key Points: 
  • Developed in Partnership with Berklee Music and Health Institute, Program Will Feature Original Music and Encourage Smokers to Listen During Smoke-Less Breaks.
  • WARREN, N.J., July 27, 2022 /PRNewswire/ -- Today, Nicorette unveilsSmokeLess Break Beats a first-of-its kind, customized music listening experience that uses the science of music therapy to address smokers' needs and motivate them towards healthier breaks.
  • Smoke breaks are ingrained in smoking culture, serving as "treasured moments" that routinely help smokers slow down and relax.
  • SmokeLess Break Beats is designed to help smokers keep the habit of taking breaks but replace the cigarette with listening to music instead," explained Dan Wertheim, Brand Manager, U.S. Smokers' Health, Haleon.

Stryker Launches PROstep™ MICA® SOLO Guide to Simplify Minimally Invasive Bunion Procedures

Retrieved on: 
Thursday, February 24, 2022
Nursing, Physical Therapy, Other Health, Health, Women, Seniors, Men, Medical Devices, Hospitals, Surgery, Consumer, PECA, FRCS, Blueprint, MICA, Ankle, Marketing, Stryker, Nicorette, Industry, Stryker Corporation, Medical and Surgical History of the War of the Rebellion, Surgeon, Medical education, Orthopedic surgery, Foot, ACFAS, Solution, Spine, Dentistry, MD

The PROstep MICA SOLO Guide is like having an expert assistant at hand to make the necessary surgical steps in this procedure much easier.

Key Points: 
  • The PROstep MICA SOLO Guide is like having an expert assistant at hand to make the necessary surgical steps in this procedure much easier.
  • The PROstep MICA SOLO Guide reflects Strykers ongoing commitment to technological innovation, and we see it playing an integral role in the future of minimally invasive foot and ankle surgery.
  • The PROstep MICA SOLO Guide will be showcased at an industry sponsored Stryker Experience event on Feb. 24 at ACFAS and will be featured at Strykers exhibit booth (614).
  • Stryker is one of the worlds leading medical technology companies and, together with its customers, is driven to make healthcare better.

Nicotine Replacement Therapy Market Size Worth $147.9 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Monday, February 15, 2021
Psychoactive drugs, Smoking cessation, Electronic cigarettes, Nicotinic agonists, Nicotine replacement therapy, Nicotine, Tobacco, Heated tobacco product, NRT, Niquitin, Nicorette

SAN FRANCISCO, Feb. 15, 2021 /PRNewswire/ -- The global nicotine replacement therapy market size is expected to reach USD 147.9 billion by2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 15, 2021 /PRNewswire/ -- The global nicotine replacement therapy market size is expected to reach USD 147.9 billion by2028, according to a new report by Grand View Research, Inc.
  • The growth of the market is largely attributed to increasing government initiatives to promote nicotine replacement therapy (NRT) products for reducing mortality due to smoking and diseases associated with it.
  • The heat-not-burn tobacco products segment is expected to grow at the fastest rate over the forecast period
    The offline distribution channel segment dominated the market in 2020.
  • Grand View Research has segmented the global nicotine replacement therapy market on the basis of product, distribution channel, and region:
    Nicotine Replacement Therapy Product Outlook (Revenue, USD Billion, 2017 - 2028)

Nicotine Replacement Therapy Market Size Worth $147.9 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Monday, February 15, 2021
Psychoactive drugs, Smoking cessation, Electronic cigarettes, Nicotinic agonists, Nicotine replacement therapy, Nicotine, Tobacco, Heated tobacco product, NRT, Niquitin, Nicorette

SAN FRANCISCO, Feb. 15, 2021 /PRNewswire/ -- The global nicotine replacement therapy market size is expected to reach USD 147.9 billion by2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 15, 2021 /PRNewswire/ -- The global nicotine replacement therapy market size is expected to reach USD 147.9 billion by2028, according to a new report by Grand View Research, Inc.
  • The growth of the market is largely attributed to increasing government initiatives to promote nicotine replacement therapy (NRT) products for reducing mortality due to smoking and diseases associated with it.
  • The heat-not-burn tobacco products segment is expected to grow at the fastest rate over the forecast period
    The offline distribution channel segment dominated the market in 2020.
  • Grand View Research has segmented the global nicotine replacement therapy market on the basis of product, distribution channel, and region:
    Nicotine Replacement Therapy Product Outlook (Revenue, USD Billion, 2017 - 2028)

Desperate Need Fuels New Products, Programs in Smoking Cessation Space

Retrieved on: 
Tuesday, September 29, 2020
Health, Articles, Human behavior, Health effects of tobacco, Habits, Nicorette, Smoking cessation, Smoking

The maker of Nicorette, GlaxoSmithKline PLC(NYSE: GSK) creates innovative nicotine replacement therapies and smoking cessation products, including theNicorette product line.

Key Points: 
  • The maker of Nicorette, GlaxoSmithKline PLC(NYSE: GSK) creates innovative nicotine replacement therapies and smoking cessation products, including theNicorette product line.
  • The need to address these disturbing statistics is urgent, and the potential benefits of doing so may include more than saving lives.
  • According to a Global Smoking Cessation Market Analysis 2019, the smoking cessation market is projected to reach $63.99 billion by 2026 , growing at a CAGR of 16.9% during 2018 to 2026.
  • In a market with a desperate need for solutions, Kaival Brands seems particularly well positioned to experience substantial growth in a space that offers huge potential.

Desperate Need Fuels New Products, Programs in Smoking Cessation Space

Retrieved on: 
Tuesday, September 29, 2020
Health, Articles, Human behavior, Health effects of tobacco, Habits, Nicorette, Smoking cessation, Smoking

The maker of Nicorette, GlaxoSmithKline PLC(NYSE: GSK) creates innovative nicotine replacement therapies and smoking cessation products, including theNicorette product line.

Key Points: 
  • The maker of Nicorette, GlaxoSmithKline PLC(NYSE: GSK) creates innovative nicotine replacement therapies and smoking cessation products, including theNicorette product line.
  • The need to address these disturbing statistics is urgent, and the potential benefits of doing so may include more than saving lives.
  • According to a Global Smoking Cessation Market Analysis 2019, the smoking cessation market is projected to reach $63.99 billion by 2026 , growing at a CAGR of 16.9% during 2018 to 2026.
  • In a market with a desperate need for solutions, Kaival Brands seems particularly well positioned to experience substantial growth in a space that offers huge potential.